Today: 2 July 2026
Browse Category

NASDAQ:ACB 7 December 2025 - 12 December 2025

Aurora Cannabis (ACB) Stock Jumps on US Marijuana Rescheduling Headlines: Today’s News, Forecasts, and Analysis (Dec. 12, 2025)

Aurora Cannabis (ACB) Stock Jumps on US Marijuana Rescheduling Headlines: Today’s News, Forecasts, and Analysis (Dec. 12, 2025)

Dec. 12, 2025 — Aurora Cannabis Inc. stock is in focus Friday as cannabis equities broadly rally on fresh reporting that President Donald Trump is considering steps to loosen federal marijuana restrictions, including directing agencies toward reclassifying marijuana as a Schedule III drug .Reuters+ 1 In pre-market trading, Aurora Cannabis rose about 15% alongside other cannabis names, reflecting how quickly US federal policy headlines can re-rate sentiment across the sector—even for Canada-based operators with international medical exposure.Investing.com+ 1
12 December 2025
Aurora Cannabis (ACB) Stock on December 7, 2025: Australia Deal, Q2 2026 Earnings and What Forecasts Say Next

Aurora Cannabis (ACB) Stock on December 7, 2025: Australia Deal, Q2 2026 Earnings and What Forecasts Say Next

Aurora Cannabis Inc. is ending 2025 in a very different place from where it started. After years of restructuring, the company has become a highly focused global medical cannabis business, with new partnerships in Australia, expanding operations in Europe, and back‑to‑back quarters of record medical revenue. As of the latest trading sessions before December 7, 2025, ACB’s U.S.-listed shares trade around US$4.60, while the TSX listing changes hands near C$6.39, giving the company a market value in roughly the US$260–280 million range. Investing.com+2Stock Titan+2
7 December 2025
···

Stock Market Today

  • IperionX (ASX:IPX) Gets Up to US$6.6M Defense Grant for Titanium Output
    July 1, 2026, 7:47 PM EDT. IperionX Limited (ASX:IPX) landed as much as US$6.6 million from a U.S. Department of Defense program to boost titanium plate and parts production at its Virginia site. The funding stacks on top of previous prototype and purchase deals. IperionX is still pre-revenue and has logged net losses over US$30 million, with investors keeping an eye on the company's execution risks. Shares are valued between A$8.87 and A$10.51, as the market weighs the company's hefty spend and ongoing losses. The contract could validate IperionX's titanium process and scale, though investors remain cautious about future performance.
Go toTop